Nevertheless, in HFpEF patients, Gal-3 levels are associated with the severity of diastolic dysfunction and LV stiffness, as well as with adverse clinical outcomes, independent of renal dysfunction and other risk factors. This evidence concerns the gene LGALS3 and Abnormal renal physiology.